Presentations
J.P. Morgan Healthcare Conference Presentation
Jan 10, 2023
Efficacy of CV-0000042, a Novel M4 Receptor Full Agonist, and CV-0000071, a Novel M4 Receptor Partial Agonist, in Preclinical In Vivo Models of Psychosis
Nov 13, 2022
Binding and Signal Profiling of Full and Partial M4 Agonists
Nov 13, 2022
Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Receptor Agonists in Modulating Amphetamine-Induced Brain Activity Assessed by Functional MRI (fMRI) in Rats
Nov 13, 2022
3Q 2022 Financial Results & Business Update
Nov 08, 2022
Cerevel Corporate Presentation - September
Sep 09, 2022
2Q 2022 Financial Results & Business Update
Aug 01, 2022
IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease
May 13, 2022
1Q 2022 Financial Results & Business Update
May 10, 2022
SIRS 2022 Presentation – Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia
Apr 08, 2022